Intensive Care Unit SyndromePRIOREANCT07417592
Study on the Priorities of Patients Admitted to Intensive Care
An observational study of Intensive Care Unit Syndrome, run by University Hospital, Brest at 1 site in France.
Trial summary
The goal of this observational study is to learn about the priorities of patients admitted to intensive care units (ICUs) who have a life-threatening condition, as well as the priorities assumed by their designated relatives and healthcare professionals (nurses, nursing assistants, ICU physicians, and general… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intensive Care Unit Syndrome
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 15 Feb 2026to 14 Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient admitted to intensive care Contact person for patients admitted to intensive care Caregiver for patients admitted to intensive care Family doctor for patients admitted to intensive care
Who may be able to join
- Adult Patient
- Estimated length of stay in intensive care exceeding 72 hours
- No objection from the patient or the designated representative, if the patient is unable to consent to participate in the study
- Adult Person
- No objection to participate in the study
- No objection to participate in the study
Who cannot join
- Patients under legal protection (guardianship, conservatorship)
- Pregnant or breastfeeding women
- Disagreement among the patient's relatives regarding the designated representative.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CHU de Brest
Brest, 29200
Thomas GARGADENNEC, MD, 02 30 33 78 94 ext. +33, thomas.gargadennec@chu-brest.fr
Thomas GARGADENNEC, MD
About this study
The goal of this observational study is to learn about the priorities of patients admitted to intensive care units (ICUs) who have a life-threatening condition, as well as the priorities assumed by their designated relatives and healthcare professionals (nurses, nursing assistants, ICU physicians, and general practitioners).
- Conditions
- Intensive Care Unit Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
Agreement rate
Assessment of the consistency between the priorities of patients and/or those assumed by the referring person and the priorities assumed by caregivers (resuscitation team and attending physician, if possible).
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start15 Feb 2026 (estimated)
- Primary completion15 Aug 2027 (estimated)
- Study completion14 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intensive Care Unit SyndromeStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07417592
- Sponsor's protocol ID
- 29BRC25.0322
- Other IDs
- 2025-A02336-43
- Acronym
- PRIOREA
- Status last verified
- Jan 2026
- First submitted
- 11 Feb 2026
- Last updated
- 5 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Priorities of Patients Admitted to Intensive Care
- ClinicalTrials.gov ID
- NCT07417592
- Acronym / sponsor ID
- PRIOREA / 29BRC25.0322
- Conditions
- Intensive Care Unit Syndrome
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 15 Feb 2026 (estimated)
- Primary completion
- 15 Aug 2027 (estimated)
- Study completion
- 14 Nov 2027 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the priorities of patients admitted to intensive care units (ICUs) who have a life-threatening condition, as well as the priorities assumed by their designated relatives and healthcare professionals (nurses, nursing assistants, ICU physicians, and general practitioners).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient admitted to intensive care Contact person for patients admitted to intensive care Caregiver for patients admitted to intensive care Family doctor for patients admitted to intensive care
Key inclusion criteria (6 listed)
- Adult Patient
- Estimated length of stay in intensive care exceeding 72 hours
- No objection from the patient or the designated representative, if the patient is unable to consent to participate in the study
- Adult Person
- No objection to participate in the study
Key exclusion criteria (3 listed)
- Patients under legal protection (guardianship, conservatorship)
- Pregnant or breastfeeding women
- Disagreement among the patient's relatives regarding the designated representative.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Agreement rate
Time frame: 48 hours
Assessment of the consistency between the priorities of patients and/or those assumed by the referring person and the priorities assumed by caregivers (resuscitation team and attending physician, if possible).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Individual participant dataSharing planned: Yes. All collected data that underlie results in a publication
Related trials for Intensive Care Unit Syndrome
Recruiting
Effect of Rutin and Vitamin C on Outcomes in Adults With Sepsis Admitted to the Intensive Care Unit
Sepsis
Not yet recruitingObservational study
Ultrasound-Calibrated Pulse Contour Cardiac Output Monitoring: Value and Accuracy in Hemodynamic Care
Sepsis, Circulatory Instability
Not yet recruiting
Feasibility Study on the Use of a Walking Exoskeleton in the Intensive Care Unit
Neuromuscular Disease in Post-Intensive Care Syndrome
Not yet recruitingObservational study
Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis
Sepsis, Septic Shock
Recruiting
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock
Sepsis - to Reduce Mortality in the Intensive Care Unit, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intensive Care Unit Syndrome, run by University Hospital, Brest at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thomas GARGADENNEC, MD (02 30 33 78 94 ext. +33, thomas.gargadennec@chu-brest.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Agreement rate (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.